Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Is routine use of renal tumor biopsy associated with lower rates of benign histology following nephrectomy for small renal masses?

Richard PO, Lavallée LT, Pouliot F, Komisarenko M, Martin L, Latouff JB, Finelli A.

J Urol. 2018 Apr 10. pii: S0022-5347(18)42925-4. doi: 10.1016/j.juro.2018.04.015. [Epub ahead of print]

PMID:
29653161
2.

Exosomes Induce Fibroblast Differentiation into Cancer-associated Fibroblasts through TGFβ Signaling.

R Goulet C, Bernard G, Tremblay S, Chabaud S, Bolduc S, Pouliot F.

Mol Cancer Res. 2018 Apr 10. pii: molcanres.0784.2017. doi: 10.1158/1541-7786.MCR-17-0784. [Epub ahead of print]

PMID:
29636362
3.

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F.

Eur Urol Focus. 2018 Mar 30. pii: S2405-4569(18)30086-5. doi: 10.1016/j.euf.2018.03.008. [Epub ahead of print]

PMID:
29609897
4.

A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis.

Azad T, Janse van Rensburg HJ, Lightbody ED, Neveu B, Champagne A, Ghaffari A, Kay VR, Hao Y, Shen H, Yeung B, Croy BA, Guan KL, Pouliot F, Zhang J, Nicol CJB, Yang X.

Nat Commun. 2018 Mar 13;9(1):1061. doi: 10.1038/s41467-018-03278-w.

5.

Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study.

Dragomir A, Aprikian A, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S.

CMAJ Open. 2017 Dec 11;5(4):E834-E841. doi: 10.9778/cmajo.20170005.

6.

Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.

Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y.

BJU Int. 2018 Mar;121(3):399-404. doi: 10.1111/bju.14041. Epub 2017 Oct 25.

PMID:
28972698
7.

Tissue-engineered human 3D model of bladder cancer for invasion study and drug discovery.

Ringuette Goulet C, Bernard G, Chabaud S, Couture A, Langlois A, Neveu B, Pouliot F, Bolduc S.

Biomaterials. 2017 Nov;145:233-241. doi: 10.1016/j.biomaterials.2017.08.041. Epub 2017 Aug 29.

PMID:
28888113
8.

Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective.

Lawson KA, Saarela O, Liu Z, Lavallée LT, Breau RH, Wood L, Jewett MAS, Kapoor A, Tanguay S, Moore RB, Rendon R, Pouliot F, Black PC, Kawakami J, Drachenberg D, Finelli A.

Can Urol Assoc J. 2017 Aug;11(8):232-237. doi: 10.5489/cuaj.4397.

9.

Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC).

Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, Vanhuyse M, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaaed S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH.

J Cancer Educ. 2017 Aug 4. doi: 10.1007/s13187-017-1259-7. [Epub ahead of print]

PMID:
28779441
10.

Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy.

Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F.

Eur Urol Focus. 2017 Feb 23. pii: S2405-4569(17)30035-4. doi: 10.1016/j.euf.2017.02.007. [Epub ahead of print]

11.

Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.

Shayegan B, Pouliot F, So A, Fernandes J, Macri J.

Can Urol Assoc J. 2017 Jun;11(6):204-209. doi: 10.5489/cuaj.4539. Review.

12.

New research in kidney cancer, ASCO-GU 2017.

Basappa N, Pouliot F.

Can Urol Assoc J. 2017 Jun;11(6Suppl2):S163-S165. doi: 10.5489/cuaj.4607. Review. No abstract available.

13.

Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.

Klotz L, Breau RH, Collins LL, Gleave ME, Pickles T, Pouliot F, Saad F.

Can Urol Assoc J. 2017 Jan-Feb;11(1-2):E62-E63. doi: 10.5489/cuaj.4494. Epub 2017 Feb 20. Review. No abstract available.

14.

Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.

Klotz L, Breau RH, Collins LL, Gleave ME, Pickles T, Pouliot F, Saad F.

Can Urol Assoc J. 2017 Jan-Feb;11(1-2):16-23. doi: 10.5489/cuaj.4303. Review.

15.

A Multicentered, Propensity Matched Analysis Comparing Laparoscopic and Open Surgery for pT3a Renal Cell Carcinoma.

Patel P, Nayak JG, Liu Z, Saarela O, Jewett M, Rendon R, Kapoor A, Black P, Tanguay S, Kawakami J, Moore R, Breau RH, Morash C, Pouliot F, Drachenberg DE.

J Endourol. 2017 Jul;31(7):645-650. doi: 10.1089/end.2016.0787.

PMID:
28381117
16.

CUA guideline on the management of cystic renal lesions.

Richard PO, Violette PD, Jewett MA, Pouliot F, Leveridge M, So A, Whelan TF, Rendon R, Finelli A.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E66-E73. doi: 10.5489/cuaj.4484. Epub 2017 Mar 16. No abstract available.

17.

Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models.

Kenmogne LC, Roy J, Maltais R, Rouleau M, Neveu B, Pouliot F, Poirier D.

PLoS One. 2017 Feb 9;12(2):e0171871. doi: 10.1371/journal.pone.0171871. eCollection 2017.

18.

Corrigendum: Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens.

Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F.

Sci Rep. 2016 Nov 21;6:37381. doi: 10.1038/srep37381. No abstract available.

19.

Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens.

Jain P, Neveu B, Velot L, Wu L, Fradet Y, Pouliot F.

Sci Rep. 2016 Sep 28;6:33968. doi: 10.1038/srep33968.

20.

Safety, reliability and accuracy of small renal tumour biopsies: results from a multi-institution registry.

Richard PO, Jewett MA, Tanguay S, Saarela O, Liu ZA, Pouliot F, Kapoor A, Rendon R, Finelli A.

BJU Int. 2017 Apr;119(4):543-549. doi: 10.1111/bju.13630. Epub 2016 Sep 7.

21.

Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients.

Gagné-Loranger M, Lacombe L, Pouliot F, Fradet V, Dagenais F.

Eur J Cardiothorac Surg. 2016 Aug;50(2):317-21. doi: 10.1093/ejcts/ezw023. Epub 2016 Mar 25.

PMID:
27016196
22.

Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.

Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C.

Cancer Prev Res (Phila). 2016 Feb;9(2):189-95. doi: 10.1158/1940-6207.CAPR-15-0069. Epub 2015 Dec 8.

23.

A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer.

Neveu B, Jain P, Têtu B, Wu L, Fradet Y, Pouliot F.

Oncotarget. 2016 Jan 12;7(2):1300-10. doi: 10.18632/oncotarget.6360.

24.

FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy.

Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F.

Cancer Imaging. 2015 Mar 3;15:2. doi: 10.1186/s40644-015-0038-0.

25.

CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.

Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, Jung ME, Huang J, Wu L.

Cancer Res. 2015 Mar 15;75(6):950-62. doi: 10.1158/0008-5472.CAN-14-0992. Epub 2015 Mar 3.

26.

New developments in the imaging of metastatic prostate cancer.

Beauregard JM, Pouliot F.

Curr Opin Support Palliat Care. 2014 Sep;8(3):265-70. doi: 10.1097/SPC.0000000000000076. Review.

PMID:
25004180
27.

Are warm ischemia and ischemia time still predictive factors of poor renal function after partial nephrectomy in the setting of elective indication?

Bessede T, Bigot P, Bernhard JC, Pignot G, Boulière F, Verhoest G, Crépel M, Salomon L, Mottet N, Bellec L, Soulié M, Ferrière JM, Pfister C, Albouy B, Pouliot F, Dujardin T, Bensalah K, Patard JJ.

World J Urol. 2015 Jan;33(1):11-5. doi: 10.1007/s00345-014-1292-7. Epub 2014 Apr 4.

PMID:
24700310
28.

Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience.

Birkhäuser FD, Pantuck AJ, Rampersaud EN, Wang X, Kroeger N, Pouliot F, Zomorodian N, Riss J, Li G, Kabbinavar FF, Belldegrun AS.

Cancer J. 2013 May-Jun;19(3):189-96. doi: 10.1097/PPO.0b013e318292e8a4.

PMID:
23708063
29.

A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo.

Pouliot F, Sato M, Jiang ZK, Huyn S, Karanikolas BD, Wu L.

Mol Ther. 2013 Mar;21(3):554-60. doi: 10.1038/mt.2012.259. Epub 2012 Dec 18.

30.

Dietary omega-3 fatty acids, genetic variation and risk of breast and prostate cancers.

Mauermann J, Pouliot F, Fradet V.

World Rev Nutr Diet. 2011;102:156-71. doi: 10.1159/000327805. Epub 2011 Aug 5. Review. No abstract available.

PMID:
21865830
31.

Prospective study comparing two techniques of renal clamping in laparoscopic partial nephrectomy: impact on perioperative parameters.

Imbeault A, Pouliot F, Finley DS, Shuch B, Dujardin T.

J Endourol. 2012 May;26(5):509-14. doi: 10.1089/end.2011.0088. Epub 2011 Aug 8.

PMID:
21823983
32.

Basic research in kidney cancer.

Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A.

Eur Urol. 2011 Oct;60(4):622-33. doi: 10.1016/j.eururo.2011.06.048. Epub 2011 Jul 5. Review.

33.

In vivo imaging of intraprostatic-specific gene transcription by PET.

Pouliot F, Karanikolas BD, Johnson M, Sato M, Priceman SJ, Stout D, Sohn J, Satyamurthy N, deKernion JB, Wu L.

J Nucl Med. 2011 May;52(5):784-91. doi: 10.2967/jnumed.110.084582. Epub 2011 Apr 15.

34.

Multivariate analysis of the factors involved in loss of renal differential function after laparoscopic partial nephrectomy: a role for warm ischemia time.

Pouliot F, Pantuck A, Imbeault A, Shuch B, Calimlim B, Audet JF, Finley DS, Dujardin T.

Can Urol Assoc J. 2011 Apr;5(2):89-95. doi: 10.5489/cuaj.10044.

35.

Ultrasound-based combination therapy: potential in urologic cancer.

Finley DS, Pouliot F, Shuch B, Chin A, Pantuck A, Dekernion JB, Belldegrun AS.

Expert Rev Anticancer Ther. 2011 Jan;11(1):107-13. doi: 10.1586/era.10.174. Review.

PMID:
21166515
36.

Quality of pathological reporting for renal cell cancer: implications for systemic therapy, prognostication and surveillance.

Shuch B, Pantuck AJ, Pouliot F, Finley DS, Said JW, Belldegrun AS, Saigal C.

BJU Int. 2011 Aug;108(3):343-8. doi: 10.1111/j.1464-410X.2010.09871.x. Epub 2010 Nov 19.

37.

Immunological therapy in urological malignancy: novel combination strategies.

Finley DS, Pouliot F, Chin AI, Shuch B, Pantuck AJ, Belldegrun AS, Dekernion JB.

Int J Urol. 2011 Feb;18(2):94-101. doi: 10.1111/j.1442-2042.2010.02664.x. Epub 2010 Nov 12. Review.

38.

Cardiac glycosides may affect prostate specific antigen levels.

Pouliot F, Wu L.

J Urol. 2010 Nov;184(5):1831-2. doi: 10.1016/j.juro.2010.08.052. Epub 2010 Sep 17. No abstract available.

PMID:
20846675
40.

Contemporary management of renal tumors with venous tumor thrombus.

Pouliot F, Shuch B, Larochelle JC, Pantuck A, Belldegrun AS.

J Urol. 2010 Sep;184(3):833-41; quiz 1235. doi: 10.1016/j.juro.2010.04.071. Review.

PMID:
20643450
41.

Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: can deep hypothermic circulatory arrest limit perioperative mortality?

Shuch B, Crispen PL, Leibovich BC, LaRochelle JC, Pouliot F, Pantuck AJ, Liu W, Crepel M, Schuckman A, Rigaud J, Bouchot O, Patard JJ, Skinner D, Belldegrun AS, Blute ML.

BJU Int. 2011 Mar;107(5):724-728. doi: 10.1111/j.1464-410X.2010.09488.x.

42.

Primary and salvage cryotherapy for prostate cancer.

Finley DS, Pouliot F, Miller DC, Belldegrun AS.

Urol Clin North Am. 2010 Feb;37(1):67-82, Table of Contents. doi: 10.1016/j.ucl.2009.11.007. Review.

PMID:
20152521
43.

Determination of success by objective scintigraphic criteria after laparoscopic pyeloplasty.

Pouliot F, Lebel MH, Audet JF, Dujardin T.

J Endourol. 2010 Feb;24(2):299-304. doi: 10.1089/end.2009.0134.

PMID:
20039822
44.

Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy.

Shuch B, Said J, LaRochelle JC, Zhou Y, Li G, Klatte T, Pouliot F, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2010 Feb 1;116(3):616-24. doi: 10.1002/cncr.24768.

45.

Editorial comment.

Pouliot F, Belldegrun A.

Urology. 2009 Sep;74(3):641-2; author reply 642. doi: 10.1016/j.urology.2009.04.012. No abstract available.

PMID:
19716921
46.

Best of the 2009 AUA Annual Meeting: Highlights from the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL.

Brawer MK, Loeb S, Partin AW, Yoshimura N, Chancellor MB, Roehrborn CG, Assimos DG, Nickel JC, Shuch B, Pouliot F, Belldegrun AS, Shapiro E.

Rev Urol. 2009 Spring;11(2):82-107. No abstract available.

47.
48.

Non-invasive molecular imaging of prostate cancer lymph node metastasis.

Pouliot F, Johnson M, Wu L.

Trends Mol Med. 2009 Jun;15(6):254-62. doi: 10.1016/j.molmed.2009.04.004. Epub 2009 May 29. Review.

49.

Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery.

Bensalah K, Pantuck AJ, Rioux-Leclercq N, Thuret R, Montorsi F, Karakiewicz PI, Mottet N, Zini L, Bertini R, Salomon L, Villers A, Soulie M, Bellec L, Rischmann P, De la Taille A, Avakian R, Crepel M, Ferriere JM, Bernhard JC, Dujardin T, Pouliot F, Rigaud J, Pfister C, Albouy B, Guy L, Joniau S, van Poppel H, Lebret T, Culty T, Saint F, Zisman A, Raz O, Lang H, Spie R, Wille A, Roigas J, Aguilera A, Rambeaud B, Martinez Piñeiro L, Nativ O, Farfara R, Richard F, Roupret M, Doehn C, Bastian PJ, Muller SC, Tostain J, Belldegrun AS, Patard JJ.

Eur Urol. 2010 Mar;57(3):466-71. doi: 10.1016/j.eururo.2009.03.048. Epub 2009 Mar 31.

PMID:
19359089
50.

Chylous ascites as a complication of laparoscopic donor nephrectomy.

Caumartin Y, Pouliot F, Sabbagh R, Dujardin T.

Transpl Int. 2005 Dec;18(12):1378-81.

Supplemental Content

Loading ...
Support Center